Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

DU-127090 Solvay/H Lundbeck.

¹Hines VA Hospital, Loyola University Chicago School of Medicine, Hines, IL 60141, USA. William.Wolf@med.va.gov

Current Opinion in Investigational Drugs (London, England : 2000)

|March 11, 2003

Summary

DU-127090, a novel mixed dopamine antagonist/serotonin agonist, is being investigated for psychosis, schizophrenia, and Parkinson's disease. Clinical trials are progressing, with Phase III trials anticipated for schizophrenia treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Using scientific abstracts to measure learning outcomes in the biological sciences.

Journal of microbiology & biology education·2013

Same author

Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.

Experimental neurology·2011

Same author

Construction and characterization of a thrombin-resistant designer FGF-based collagen binding domain angiogen.

Biomaterials·2007

Same author

Effects of acute tryptophan depletion on negative symptoms and smoking topography in nicotine-dependent schizophrenics and nonpsychiatric controls.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2005

Area of Science:

Pharmacology
Neuroscience
Clinical Drug Development

Background:

DU-127090 is a novel therapeutic agent developed by Solvay and H Lundbeck.
It exhibits a mixed dopamine antagonist and serotonin agonist profile.
This dual action suggests potential efficacy in neurological and psychiatric disorders.

Purpose of the Study:

To evaluate DU-127090 as a potential treatment for psychosis and schizophrenia.
To assess the safety and efficacy of DU-127090 in early-stage clinical trials for Parkinson's disease.

Main Methods:

Phase II clinical trials are underway to assess DU-127090 for psychosis and schizophrenia.
Phase I clinical trials are being conducted to evaluate DU-127090 for Parkinson's disease.

Main Results:

Phase II trials for psychosis and schizophrenia were ongoing as of August 2002.
H Lundbeck projected the initiation of Phase III trials for schizophrenia in 2003.
An NDA filing was anticipated post-2004 for schizophrenia treatment.

Conclusions:

DU-127090 demonstrates potential as a therapeutic agent for schizophrenia and psychosis.
Further clinical development is planned, including Phase III trials.
The drug is also being explored for Parkinson's disease treatment.

Related Experiment Videos